EUVIMEDEUVIMED entdecken
Metaanalyse

Abstract 7200: Efficacy of Baxdrostat for Control of Treatment-Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials

Syeda Vilay Zehra Rizvi, Kanza Farhan, Muhammad Omar Larik, Sabika Fatima, Syeda Umme Abiha Rizvi, Shafaq Jabeen, Amr Elboliney, Ahmed E Mohamed, Muhammad Jibran, Abdullah Ghuman, Nihar Jena, Jibran Ikram und 1 weitere

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.7200 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Syeda Vilay Zehra Rizvi und 12 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertension is one of the primary contributors to the global burden of non-communicable diseases. Individuals who maintain blood pressure levels above the target range, despite being on maximally tolerated doses of three or more different classes of antihypertensive drugs, are classified as treatment-resistant hypertension. This systematic review and meta-analysis will explore the efficacy and safety of baxdrostat, an aldosterone synthase inhibitor, in treatment-resistant hypertension.

Methods

A systematic search was performed from inception to September 15, 2025. Quantitative synthesis was performed using Review Manager software (version 5.4). Continuous outcomes were reported as mean difference (MD) and dichotomous outcomes were reported as risk ratio (RR), along with their 95% confidence intervals (CI).

Results

Four randomized controlled trials (RCTs) were included. For systolic blood pressure (SBP), baxdrostat demonstrated a statistically significant reduction in both 1 mg and 2 mg doses (MD: -6.19, P = 0.010; MD: -7.90, P < 0.00001, respectively). For diastolic blood pressure (DBP), baxdrostat demonstrated a statistically significant reduction in both 1 mg and 2 mg doses (MD: -2.66, P = 0.03; MD: -3.12, P = 0.004, respectively). Baxdrostat was associated with increased risk of any adverse events in both doses (RR: 1.23, P = 0.004; RR: 1.23, P = 0.04, respectively), but no differences were observed for severe adverse events. Importantly, hyperkalemia was significantly associated in both 1 mg and 2 mg doses (RR: 4.43, P = 0.0007; RR: 5.68, P = 0.04, respectively).

Conclusion

In conclusion, baxdrostat significantly lowers SBP and DBP in treatment-resistant hypertension at all doses. In terms of safety profile, baxdrostat was associated with any adverse events, including hyperkalemia, at both doses, but not related to severe adverse events. This novel class represents a promising therapeutic advancement, although further phase III trials are needed to arrive at a valid conclusion.

Zitieren

APA

Rizvi, S. V. Z., Farhan, K., Larik, M. O., Fatima, S., Rizvi, S. U. A., Jabeen, S., Elboliney, A., Mohamed, A. E., Jibran, M., Ghuman, A., Jena, N., Ikram, J., & alam, M. (2026). Abstract 7200: Efficacy of Baxdrostat for Control of Treatment-Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.7200

Vancouver

Rizvi SVZ, Farhan K, Larik MO, Fatima S, Rizvi SUA, Jabeen S, et al. Abstract 7200: Efficacy of Baxdrostat for Control of Treatment-Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.7200

BibTeX
@article{Rizvi2026,
  author = {Rizvi, Syeda Vilay Zehra and Farhan, Kanza and Larik, Muhammad Omar and Fatima, Sabika and Rizvi, Syeda Umme Abiha and Jabeen, Shafaq and Elboliney, Amr and Mohamed, Ahmed E and Jibran, Muhammad and Ghuman, Abdullah and Jena, Nihar and Ikram, Jibran and alam, mahboob},
  title = {Abstract 7200: Efficacy of Baxdrostat for Control of Treatment-Resistant Hypertension: A Meta-Analysis of Randomized Controlled Trials},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.7200}
}
Kostenlos starten →